News

Pat Livney, founder and CEO of Cure CMT, recently addressed the 2025 CMT Patient Meeting in Beijing, announcing exciting plans to launch clinical trials in China next year and bringing hope to the growing community of Charcot-Marie-Tooth disease patients in the region.

The meeting, themed “Creating Hope, Embracing the Future,” was organized by Qianlixing CMT Support Home, a prominent Chinese patient organization that has been instrumental in supporting CMT patients across China. The event brought together doctors, patients, and researchers in what organizers described as a truly meaningful gathering for the CMT community.

Livney, who has been a pivotal figure in CMT research and advocacy since 2008, delivered remarks that generated significant excitement among attendees when he shared plans to initiate clinical trials in Beijing in 2025. His announcement comes at a crucial time as the global CMT research landscape continues to evolve rapidly.

Recent research indicates that the CMT field is experiencing significant advances in genetic diagnosis and disease recognition, with international networks and patient organization partnerships proving vital for progress. China has emerged as a major player in clinical trials, recently surpassing the United States in the annual number of ongoing clinical trials, making it an increasingly important location for CMT research initiatives.

Following his presentation, Livney received a Certificate of Appreciation from Qianlixing CMT Support Home in recognition of his enduring contributions to the fight against rare diseases. The organization has been actively supporting CMT research efforts, including participation in national cross-sectional studies that have helped better understand the health status of CMT patients in China.

“Your expertise and compassion have offered patients invaluable support and have been a source of inspiration to us all,” organizers noted in their message to Livney. “The meeting was a true success, filling attendees with confidence and hope for the future.”